US 100% Pharma Tariffs: Singapore's Industry Navigates Uncertainty Amid Global Supply Chain Concerns
AI-Generated Summary
The US has announced a new 100% tariff on branded or patented pharmaceutical products, creating significant uncertainty for Singapore's pharmaceutical sector, a major exporter to the US. Industry players and experts are monitoring the situation, expressing concerns over potential ripple effects on global supply chains, affordability, and patient access. The full impact remains unclear, depending on policy specifics and companies' manufacturing footprints.
In a nutshell
This development underscores the profound influence of trade policy on the pharmaceutical industry, highlighting the complex interplay between national interests, global manufacturing strategies, and patient access to essential medicines. It challenges industry leaders to reassess supply chain resilience and market strategies in an evolving regulatory landscape.
Source: CNA
